Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 30, 2016HaematologicaOpen Access

Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system

View Full Paper
Ask AI
Bookmark
Share

Authors

TPThomas PrébetBristol-Myers Squibb (United States)Pierre FenauxPierre FenauxUniversité Claude Bernard Lyon 1NVNorbert VeyInstitut Paoli-Calmettes

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Prébet et al. (2016) studied this question.

synapsesocial.com/papers/6a851fdc0743ff3319d979behttps://doi.org/10.3324/haematol.2016.150714
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Decitabine improves patient outcomes in myelodysplastic syndromes2006 · 1,539 citations
  2. 2Revised International Prognostic Scoring System for Myelodysplastic Syndromes2012 · 3,202 citations
  3. 3The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure2016 · 38 citations
  4. 4Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure2012 · 57 citations
  5. 5Outcome of patients with low-risk myelodysplasia after azacitidine treatment failure2012 · 30 citations